OLD National Bancorp IN lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.9% in the 1st quarter, Holdings Channel reports. The firm owned 26,140 shares of the biopharmaceutical company’s stock after selling 3,869 shares during the period. OLD National Bancorp IN’s holdings in Gilead Sciences were worth $1,699,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Athena Capital Advisors LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $27,000. Capital Financial Planning LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $27,000. Creative Financial Designs Inc. ADV lifted its holdings in shares of Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 165 shares during the last quarter. Claybrook Capital LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $32,000. Finally, We Are One Seven LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $37,000. 78.68% of the stock is owned by institutional investors and hedge funds.
GILD has been the topic of a number of recent analyst reports. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, April 22nd. Oppenheimer set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, April 22nd. Wells Fargo & Co lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $95.00 to $68.00 in a research report on Monday, February 11th. Citigroup reissued a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 5th. Finally, Raymond James set a $83.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, May 3rd. Nine analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $81.00.
Shares of NASDAQ:GILD opened at $66.50 on Thursday. The company has a market cap of $84.81 billion, a PE ratio of 10.81, a P/E/G ratio of 0.81 and a beta of 1.14. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company posted $1.48 earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.79%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: What is insider trading?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.